https://www.selleckchem.com/products/gdc-0068.html
In total, 17 participants completed the study. Change from baseline in the EPB on Day 19 for all three doses of PF-06763809 was not significantly different from that of vehicle (P0.05). A significant reduction in EPB from baseline was observed with betamethasone on Day 19 relative to all other treatments (P0.0001). Treatment-related adverse events were mild/moderate. There were no significant differences in gene expression on Day 19 between vehicle and PF-06763809-treated skin lesions. Using a psoriasis plaque test design, PF-0
Like
Comment
Share
